Abstract The translation of pharmacological treatments for alcohol use disorder (AUD) remains challenging despite advances in neuroscientific and molecular sciences enabling unprecedented levels of analysis. We propose that formal characterization of pre-clinical discrete choice procedures with human decision-making models offers a solution. We review evidence supporting choice procedures in the screening of pharmacological treatments and the remarkable success of sequential sampling models in e